Xellia To Invest $25 Million to Expand Sterile Drug Product ManufacturingBy
Xellia Pharmaceuticals, a Copenhagen, Denmark-headquartered specialty pharmaceutical company focused on anti-infective treatments, has broken ground on a new $25-million facility for sterile manufacturing at its Copenhagen site, which is the location of the company’s headquarters and the company’s largest product manufacturing plant.
The company began construction of a new 1,000-square meter multi-story building for sterile manufacturing earlier this month.
Xellia’s Copenhagen site is responsible for manufacturing, stability testing, and packaging of both sterile active pharmaceutical ingredients (APIs) and the finished-dosage forms for anti-infectives such as vancomycin, and colistmethate sodium.
In addition, over the past 15 months, the company has expanded several of its sites. In the US, the company has been expanding production capacity for sterile injectable products. In addition to Xellia’s Raleigh, North Carolina site, a new production facility in Cleveland, Ohio received notification from the US Food and Drug Administration in November 2016 to allow packaging and distribution of drug products at the site. Full manufacturing of products is anticipated during 2018.
In August 2017, the company also completed the expansion of a new $13-million, 3,000-square-meter, multi-story Centralized Laboratory Services building at Xellia’s Budapest, Hungary, manufacturing site. The expanded building, located next to Xellia’s current API manufacturing plant, gives the company additional product-stability and release-testing expertise and capabilities.
The company also expanded it R&D team with more than 15 new scientists and approximately 1,000 square-meters of new lab space at its Center of Excellence in Zagreb, Croatia in September 2016. The Xellia Zagreb site, now has approximately 100 highly skilled employees, who are working to improve the efficacy, safety and delivery of existing anti-infectives, reduce toxic side effects, and develop drug-device combination antimicrobial therapies.
Source: Xellia Pharmaceuticals